Scarica l'app Stockscreener
140.71
0.80%
-1.13
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$141.84
Aprire:
$140.94
Volume 24 ore:
1.98M
Relative Volume:
1.58
Capitalizzazione di mercato:
$14.30B
Reddito:
$3.10B
Utile/perdita netta:
$668.60M
Rapporto P/E:
21.63
EPS:
6.5044
Flusso di cassa netto:
$831.30M
1 W Prestazione:
+1.27%
1M Prestazione:
-10.24%
6M Prestazione:
+6.15%
1 anno Prestazione:
+2.71%
Intervallo 1D:
$139.61
$143.74
Intervallo di 1 settimana:
$136.31
$143.74
Portata 52W:
$122.14
$186.12
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Nome
Neurocrine Biosciences Inc
Settore
Telefono
(858) 617-7600
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
140.71 | 14.07B | 3.10B | 668.60M | 831.30M | 6.5044 |
TAK
Takeda Pharmaceutical Co Adr
|
17.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.31 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.72 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
69.10 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
571.38 | 20.39B | 3.17B | 1.29B | 1.01B | 27.09 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | Iniziato | Citigroup | Buy |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2025-04-15 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-14 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Ripresa | Citigroup | Neutral |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Reiterato | Mizuho | Neutral |
| 2023-07-24 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-30 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-09-26 | Iniziato | Wells Fargo | Equal Weight |
| 2022-06-06 | Ripresa | Jefferies | Buy |
| 2022-03-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Underperform |
| 2021-11-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-08-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-05-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Iniziato | Raymond James | Outperform |
| 2020-09-30 | Iniziato | The Benchmark Company | Hold |
| 2020-08-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Downgrade | Goldman | Buy → Neutral |
| 2020-06-09 | Iniziato | Wedbush | Outperform |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-24 | Iniziato | William Blair | Outperform |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-13 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-05 | Iniziato | Guggenheim | Neutral |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-02-06 | Reiterato | BofA/Merrill | Buy |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-11-21 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
Neurocrine Biosciences, Inc. (NBIX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Neurocrine to present Prader-Willi syndrome research at FPWR event - Investing.com
Neurocrine to present Prader-Willi syndrome research at FPWR event By Investing.com - Investing.com Nigeria
Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference - PR Newswire
Learn Why The Bull Case For Neurocrine Biosciences Stock Could Change Following CMO Return - Simply Wall Street
Neurocrine Biosciences, Inc. (NBIX) Stock forecasts - Yahoo Finance Australia
Neurocrine Biosciences selects Ruder Finn as communications AOR - Medical Marketing and Media
Neurocrine Biosciences, Inc. (NBIX) stock price, news, quote and history - uk.finance.yahoo.com
Neurocrine Price Target Cut to $214.00/Share From $231.00 by UBS - Moomoo
UBS cuts Neurocrine Biosciences stock price target to $214 on competition - Investing.com
ETFs Investing in Neurocrine Biosciences, Inc. Stocks - TradingView
EBITDA margin % of Neurocrine Biosciences, Inc. – HAN:NB3 - TradingView
Neurocrine Biosciences (NBIX) Could Be 34% Undervalued After Its CMO Return - Simply Wall Street
Neurocrine Biosciences names Eiry Roberts as chief medical officer - Investing.com
Neurocrine Biosciences Names Eiry Roberts Chief Medical Officer - marketscreener.com
Neurocrine names Eiry Roberts chief medical officer - Stock Titan
Neurocrine Biosciences, Inc. Announces Chief Medical Officer Changes - marketscreener.com
Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer - PR Newswire
SLNO Stock Soars Over 39% — What’s Fueling The Rally? - stocktwits.com
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo! Finance Canada
Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last? - Eastern Progress
Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit - Yahoo Finance
Trading Systems Reacting to (NBIX) Volatility - Stock Traders Daily
Zacks.com featured highlights include NVIDIA, Neurocrine Biosciences and Ball - Eastern Progress
RBC Cuts Price Target on Neurocrine Biosciences to $187 From $198, Keeps Outperform Rating - marketscreener.com
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a Promising 43% Potential Upside - DirectorsTalk Interviews
Is Phase 4 Success Altering The Investment Case For Neurocrine Biosciences Stock? - webull.com
Neurocrine Biosciences stock draws support from strong Q2 figures - AD HOC NEWS
Neurocrine’s (NBIX) Data Deluge Reshapes A Familiar Growth Story - Yahoo Finance
NEUROCRINE BIOSCIENCES INC (NASDAQ: NBIX) Grants 3,587 Shares to CSO Onyia Jude at No Cost - Kalkine Media
Neurocrine Biosciences chief corp. affairs officer David Boyer sells $130k in stock - Investing.com Nigeria
Neurocrine Biosciences Inc (NBIX) Shares Fall 4.6% -- What GF Sc - GuruFocus
Neurocrine Biosciences (NBIX) CMO reports stock vesting, no market sale - Stock Titan
Neurocrine Biosciences (NASDAQ: NBIX) director logs 14,343-share vesting, 7,839 withheld for taxes - Stock Titan
Performance grant hands 4,483 shares to Neurocrine (NBIX) regulatory chief - stocktitan.net
Neurocrine Biosciences (NBIX) grants HR chief 3,587 shares - Stock Titan
PRSU vest gives Neurocrine Biosciences (NBIX) officer 3,587 shares - stocktitan.net
CFO at Neurocrine Biosciences (NBIX) sells shares after performance award vests - Stock Titan
Is Neurocrine Biosciences (NBIX) Still Undervalued As It Heads Into September Conferences? - Simply Wall Street
Neurocrine (NASDAQ: NBIX) officer signals potential $361K stock sale - Stock Titan
Neurocrine (NASDAQ: NBIX) officer plans $736K stock sale - Stock Titan
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring A 34.93% Potential Upside - DirectorsTalk Interviews
NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Drug Safety Warnings - Stocktwits
Behavioral Patterns of NBIX and Institutional Flows - Stock Traders Daily
Neurocrine Biosciences CCO Eric Benevich sells $333k in stock By Investing.com - Investing.com Australia
Neurocrine Biosciences at Cantor healthcare conference: growth broadens By Investing.com - Investing.com Nigeria
Transcript : Neurocrine Biosciences, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 08:35 AM - marketscreener.com
Neurocrine Biosciences at Wells Fargo conference: growth story broadens By Investing.com - Investing.com Canada
Officer at Neurocrine (NASDAQ: NBIX) plans 2,154-share sale in 2026 - Stock Titan
Neurocrine Biosciences at Wells Fargo conference: growth story broadens - Investing.com
Neurocrine Biosciences stock rating reaffirmed by RBC Capital - Investing.com Nigeria
Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Neurocrine Biosciences Inc Azioni (NBIX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ABERNETHY MATT | Chief Financial Officer |
Sep 14 '26 |
Sale |
157.20 |
2,311 |
363,285 |
42,808 |
2.77%
5.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):